Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-Mutated or Overexpres

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Alejandro Recio Boiles
Sponsor
Boehringer Ingelheim Pharmaceuticals, Inc
Unit
Cancer Center Division